Inspired by Saloni Dattani’s clinical trial bottlenecks game

If AI found a better treatment for every deadly disease, what would it cost to prove it?

Getting new helpful medicines to patients is hard, and historically it’s been getting harder. From 1950 to 2010, the number of new approved drugs per billion dollars of R&D spending halved roughly every nine years. In 2012, Jack Scannell and colleagues called this Eroom’s law, or “Moore’s law backwards”.1 One theory that explains this is the “better than the Beatles” problem: we’ve already made substantial progress on various diseases, and statistically speaking, it requires more and more patients (and therefore more and more funding) to demonstrate marginal improvements — just like how the next generation of pop stars needs to compete with the Beatles catalogue.

Despite that progress, the global burden of disease is still enormous. Most positive visions of the future put forward by AI leaders today involve the use of AI to accelerate the eradication of this burden.2 But even if AI produces a miracle drug for every disease, we still need to run the clinical trials to prove that things are getting better.

Saloni Dattani recently made a fun game to help illustrate the challenges in running these sorts of clinical trials.3 My main takeaway is that making trials go faster requires a lot of different innovations to come together; as per Amdahl’s law,4 there’s no quick fix.

This page is about the cost of measuring that progress:

The question

Suppose AI found, for every deadly disease in the world, a therapy that cuts the chance of its worst outcomes in half compared with the best treatment available today. What would it cost to prove that in pivotal trials?

The answer

What is a benevolent coordinator? An idealised planner who runs the world’s pivotal trials as a single programme to best address the global disease burden. So no duplicate or competing trials.

This is only the cost of proving that it all works. Discovery, earlier-phase trials, manufacturing, delivery and access all cost more, and are much harder to predict. Conditions that cause illness but rarely kill, such as depression or back pain, are not on the list, so “every disease” would cost more.

How the estimate works

List the diseases, price one pivotal trial for each, then add them up:

1

List the diseases

From the Global Burden of Disease (GBD) study’s list of causes of death from disease, excluding injuries and catch-all groups like “other cardiovascular diseases”, which bundle many conditions no one trial could cover.5 Use one pivotal trial per disease.

2

Get the baseline from today’s best care

Find an RCT that tested what international guidelines recommend today. Among the patients who received it, take their risk of a bad outcome over that trial’s duration, p0.

3

Size a trial to beat it 2×

Work out how many participants a new trial would need to reliably show the risk halving, from p0 to p0/2. Standard hypothesis-testing maths gives the total, N (90% power, 5% significance).

4

Price and add up

N × $53,904 per participant, summed over diseases. That is Moore et al.’s median cost per participant of a pivotal trial, adjusted to 2026 dollars.6,7 See the maths ↓

deadly diseases, and what it would cost to prove a better treatment for each

Each dot is one way a trial could measure success: a bad event, such as death or a heart attack, that the new treatment would need to make half as common. Rarer events need bigger, more expensive trials. The black tick marks the median cost for each disease, which is what the total adds up. Hover overTap a dot to see the trial its numbers come from.

Sort by

What to make of this

The headline number surprised me in how small it was. In 2024 the global pharmaceutical industry spent something like on phase 3 trials (in 2026 dollars). I expected the bill for every major disease to be far bigger, even with a benevolent coordinator in charge.

Part of the cost gap is the size of the assumed improvements. Halving the risk of a disease’s worst outcomes is a lot of progress, which needs fewer participants to produce significant results than standard clinical trials. In the pivotal trials establishing today’s best care, the risk of the bad outcomes was cut by a median of . Proving improvements of that size, rather than halvings, would cost about in total.

The other part is redundancy. Many companies compete to treat the same patients: by 2022 there were 5,683 trials testing drugs that block a single immune pathway, PD-1/PD-L1. This got so crowded that combination trials started to outstrip patient demand and the FDA had to call on drugmakers to collaborate to minimise redundancy.8 A newer immune target, TIGIT, has drawn 21 companies developing 30 drugs: about 49,000 patients in 220 trials, at an estimated cost of $3.1–3.6 billion.9 Across the drug R&D pipeline, the number of cancer drugs in development per target rose from 1.8 in 2000 to 9 in 2022.10 The effort is lopsided too in terms of global welfare: cancer accounts for 38% of industry trial starts,11 but 18% of the world’s deaths.5

What would a better-coordinated system look like? During the pandemic, the UK’s RECOVERY trial combined research efforts across NHS hospitals. It showed that dexamethasone reduced deaths among patients hospitalised with COVID-19 without requiring different groups to reproduce trial arms separately.12 I-SPY 2 ran a similar platform trial for breast cancer for more than a decade.13

Other industries have also successfully achieved better coordination to avoid redundancy across firms: in 1987, 14 US chipmakers formed SEMATECH to share pre-competitive manufacturing research. I’m not familiar with the field, but it seems to be widely credited with helping the US recover against Japanese competition.14 Maybe a better system for medicine would look similar: shared trial platforms that companies compete to put their drugs into, rather than dozens of near-identical trials competing for the same patients.

How the numbers are calculated

How many people a trial needs

Let p0 be the chance that the bad outcome happens within a fixed follow-up window on today's best care. A therapy that halves it brings the chance down to p1 = p0/2. The trial splits people equally between the new therapy and best care. It must be large enough that a real halving is detected 90% of the time (power), with no more than a 5% chance of a false alarm (two-sided significance). The standard formula for comparing two proportions gives the number of people n in each arm:

n= (A+B)2 (p0−p1)2 A= z1−α/2 2p‾(1−p‾) B= z1−β p0(1−p0)+p1(1−p1)

Here z1−α/2 = 1.96 and z1−β = 1.28 are the standard normal values for 5% two-sided significance and 90% power, and p̄ = (p0 + p1)/2. The total across both arms is N = 2n. The trial's cost is then N × $53,904: Moore et al.’s median estimated cost per participant across 225 pivotal trials ($41,413), which I assume is in 2019 dollars and adjust by US consumer prices to 2026.6,7 This is a fixed-time approximation, not the event-driven survival design many real trials use.

Why rare outcomes are expensive

The gap a trial has to detect, p0 − p1 = p0/2, is squared in the denominator. So the rarer an outcome already is on good care, the more people it takes to see it halve.

Risk todayHalvedPeople needed

Industry spending on phase 3 trials

PhRMA’s member companies spent 27–39% of their R&D on phase 3 trials in 2024.15 Applying that share to the $288 billion global total16 and adjusting to 2026 dollars7 gives about .

Sources

  1. Scannell J.W., Blanckley A., Boldon H., Warrington B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery 11:191–200.
  2. Amodei D. (2024). Machines of Loving Grace: How AI Could Transform the World for the Better. October 2024.
  3. Dattani S. (2026). The clinical trial bottlenecks game. Clinical Trials Abundance; interactive game.
  4. Amdahl G.M. (1967). Validity of the single processor approach to achieving large scale computing capabilities. AFIPS Spring Joint Computer Conference, 483–485.
  5. GBD 2023 Causes of Death Collaborators (2025). The Lancet; GBD 2023 on GHDx. Global deaths, all ages, 2023, with 95% uncertainty intervals.
  6. Moore T.J., Heyward J., Anderson G., Alexander G.C. (2020). Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study. BMJ Open 10:e038863. Medians: $41,413 per patient, $3,685 per patient visit, in current US dollars (assumed here to be 2019 dollars). These are estimates from a commercial cost-modelling tool, not audited spending.
  7. U.S. Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers (CPI-U), all items, U.S. city average, series CUUR0000SA0: 2019 annual average 255.657; 2024 annual average 313.689; 2026 average of January–October 332.769 (ratio 1.302).
  8. Upadhaya S. et al. (2022). Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nature Reviews Drug Discovery; summarised in The ASCO Post, 14 February 2022.
  9. Zhang E.H., Osipenko L., Hickman J.A. (2026). Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitors. BMJ Oncology 5:e001037. Patient numbers and costs are the authors’ estimates across candidates and trial phases.
  10. Fougner C., Cannon J., The L., Smith J.F., Leclerc O. (2023). Herding in the drug development pipeline. Nature Reviews Drug Discovery 22:617–618. Authors are McKinsey & Company employees; analysis funded by McKinsey’s Life Sciences practice. Full text (PDF).
  11. Correa D., Caveney E. (2026). Therapeutic areas driving clinical trial growth. IQVIA blog, 7 May 2026, citing IQVIA Institute Global R&D Trends 2026: oncology was 38% of industry-sponsored phase 1–3 trial starts in 2025.
  12. RECOVERY Collaborative Group (2021). Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine 384:693–704 (published online July 2020).
  13. Barker A.D., Sigman C.C., Kelloff G.J., Hylton N.M., Berry D.A., Esserman L.J. (2009). I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology & Therapeutics 86:97–100.
  14. Wessner C., Howell T. (2023). Implementing the CHIPS Act: Sematech’s lessons for the National Semiconductor Technology Center. Center for Strategic and International Studies, 19 May 2023.
  15. PhRMA (2025). 2025 Annual Membership Survey, Table 3 (R&D by function, 2024): phase III was $28.6 billion of member companies’ $104.3 billion R&D, or 27.4%; 30% of spending is uncategorised, so phase III is 39% of the spending broken down by phase.
  16. Manalac T. (2025). Undeterred by political, economic headwinds, pharma ups R&D investment in 2024 and beyond. BioSpace, 28 May 2025, reporting Evaluate Pharma World Preview 2025 data: global pharmaceutical R&D of nearly $288 billion in 2024.

Written and designed by Conor Igoe, using Kosmos.